References
- 1
Adams DH, Close S, Farmen M. et al .
Dopamine receptor D3 genotype association with greater acute positive symptom remission
with olanzapine therapy in predominately caucasian patients with chronic schizophrenia
or schizoaffective disorder.
Hum Psychopharmacol.
2008;
23
267-274
- 2
American Psychiatric Association
.Diagnostic and Statistical Manual of Mental Disorders. DSM-IV. 4th edition.. Washington
DC: American Psychiatric Association; 1994
- 3
Andreasen NC, Carpenter Jr WT.
Diagnosis and classification of schizophrenia.
Schizophrenia Bull.
1993;
19
199-214
- 4
Carpenter Jr WT, Heinrichs DW, Wagman AM.
Deficit and nondeficit forms of schizophrenia: the concept.
Am J Psychiatry.
1988;
145
578-583
- 5
Chagnon YC, Merette C, Bouchard RH. et al .
A genome wide linkage study of obesity as secondary effect of antipsychotics in multigenerational
families of eastern Quebec affected by psychoses.
Mol Psychiatry.
2004;
9
1067-1074
- 6
de Leon J.
The future (or lack of future) of personalized prescription in psychiatry.
Pharmacol Res.
2009;
59
81-89
- 7
Gupta M, Bhatnagar P, Grover S. et al .
Association studies of catechol-O-methyltransferase (COMT) gene with schizophrenia
and response to antipsychotic treatment.
Pharmacogenomics.
2009;
10
385-397
- 8 Guy W. Clinical global impression. In: ECDEU Assessment Manual for Psychopharmacology:
National Insitute of Mental Health. 1976: 217-222
- 9
Harrison PJ.
Schizophrenia susceptibility genes and their neurodevelopmental implications: focus
on neuregulin 1.
Novartis Found Symp.
2007;
288
246-255
discussion 255–249, 276–281
- 10
Ikeda M, Yamanouchi Y, Kinoshita Y. et al .
Variants of dopamine and serotonin candidate genes as predictors of response to risperidone
treatment in first-episode schizophrenia.
Pharmacogenomics.
2008;
9
1437-1443
- 11
Inada T, Koga M, Ishiguro H. et al .
Pathway-based association analysis of genome-wide screening data suggest that genes
associated with the gamma-aminobutyric acid receptor signaling pathway are involved
in neuroleptic-induced, treatment-resistant tardive dyskinesia.
Pharmacogenet Genomics.
2008;
18
317-323
- 12
Kay SR, Fiszbein A, Opler LA.
The positive and negative syndrome scale (PANSS) for schizophrenia.
Schizophrenia Bull.
1987;
13
261-276
- 13
Lee HY, Kim DJ, Lee HJ. et al .
No association of serotonin transporter polymorphism (5-HTTVNTR and 5-HTTLPR) with
characteristics and treatment response to atypical antipsychotic agents in schizophrenic
patients.
Prog Neuropsychopharmacol Biol Psychiatry.
2009;
33
276-280
- 14
Lencz T, Robinson DG, Xu K. et al .
DRD2 promoter region variation as a predictor of sustained response to antipsychotic
medication in first-episode schizophrenia patients.
Am J Psychiatry.
2006;
163
529-531
- 15
Malhotra AK, Lencz T, Correll CU, Kane JM.
Genomics and the future of pharmacotherapy in psychiatry.
Int Rev Psychiatry.
2007;
19
523-530
- 16
McClay JL, Adkins DE, Aberg K. et al .
Genome-wide pharmacogenomic analysis of response to treatment with antipsychotics.
Mol Psychiatry.
2009;
Sep 1 [Epub ahead of print]
- 17
Murray RM, O’Callaghan E, Castle DJ. et al .
A neurodevelopmental approach to the classification of schizophrenia.
Schizophrenia Bull.
1992;
18
319-332
- 18
Need AC, Keefe RS, Ge D. et al .
Pharmacogenetics of antipsychotic response in the CATIE trial: a candidate gene analysis.
Eur J Hum Genet.
2009;
17
946-957
- 19
van Os J, Burns T, Cavallaro R. et al .
Standardized remission criteria in schizophrenia.
Acta Psychiatr Scand.
2006;
113
91-95
Correspondence
C. HoyerMD, MPhil
Department of Psychiatry and Psychotherapy
Central Institute of Mental Health
J5
68159 Mannheim
Germany
Phone: +49/621/1703 2331
Fax: +49/621/1703 2325
Email: hoyer@cimh.de
